University of North Carolina - Hillsborough Campus
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McGuire, Kandace
NCT03927027: Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Active, not recruiting
3
534
US
Isosulfan Blue, Axillary Lymph Node Dissection, ALND, axillary dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
11/26
01/27
POWER, NCT04272801: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

Active, not recruiting
2
83
US
tamoxifen, letrozole, anastrozole, or exemestane, Endocrine therapy, Patient reported outcomes, surveys, questionnaires
Shayna Showalter, MD
Breast Cancer Female
06/24
06/25
Gallagher, Kristalyn
NCT03927027: Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Active, not recruiting
3
534
US
Isosulfan Blue, Axillary Lymph Node Dissection, ALND, axillary dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
11/26
01/27
TBCRC 037, NCT02206984: Endocrine Response in Women With Invasive Lobular Breast Cancer

Completed
2
201
US
Tamoxifen, Anastrozole, Fulvestrant
Priscilla McAuliffe
Breast Cancer
07/24
07/24
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
12/24
01/25
COMET, NCT02926911: Comparing an Operation to Monitoring, With or Without Endocrine Therapy () Trial For Low Risk DCIS

Active, not recruiting
N/A
997
US
Surgery, Active Monitoring
Alliance Foundation Trials, LLC., Duke University, Dana-Farber Cancer Institute, New York University, Washington University School of Medicine, Patient-Centered Outcomes Research Institute, The University of Texas MD Anderson Cancer Center, Rising Tide Foundation, Breast Cancer Research Foundation
DCIS, Ductal Carcinoma in Situ
06/24
07/28

Download Options